Tirzepatide is a dual agonist — it acts at two incretin receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). That dual activity is what makes it a distinct subject in metabolic-signaling research compared with single-receptor agonists.
Research context
In controlled research models, tirzepatide is investigated for how simultaneous GIP and GLP-1 receptor activation influences glucose-regulation and energy-balance pathways. It belongs to the broader incretin receptor agonist class, alongside semaglutide and retatrutide.
Molecular identity
Tirzepatide carries the molecular formula C225H348N48O68 and is supplied as a lyophilized powder verified to ≥98% HPLC purity with a batch-specific Certificate of Analysis — see how to read a COA.
How it's supplied
Research vials are reconstituted with a solvent such as bacteriostatic water per a laboratory's validated protocol. Product page: Tirzepatide research vials.
Research Use Only. V8 Peptides products are supplied strictly for laboratory research and development and are not intended for human or veterinary use, consumption, or any therapeutic or diagnostic purpose.